Loading...
 
Back to the list
Mediterr J Rheumatol 2021;32(2):118-23
Article Links
Musculoskeletal Disorders in Chronic Obstructive Airway Diseases: A Neglected Clinical Entity
C. Mohan Rao1, Pratima Singh1, Debashis Maikap2, Prasanta Padhan2
Authors Information

1. Department of Pulmonary Medicine, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India
2. Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India

Keywords: COPD, Skeletal muscle, osteoporosis
References
  1. Celli BR, Augusti A. COPD:time to improve its taxonomy: ERJ Open Res 2018 4(1):00132-2017.
  2. GBD 2017 Causes of death Collaborators. Global, regional and national age-sex specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systemic analysis for the Global Burden of Disease Study 2017.Lancet 2018;392:1736-88.
  3. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 2017;389:1931-40. 
  4. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom 2018 Apr 6;3:e4.
  5. Hemminki K, Liu X, Ji J, Sundquist K, Sundquist J. Subsequent COPD and lung cancer in patients with autoimmune disease. Eur Respir J 2011;37:463-5.
  6. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2012;45:291-300.
  7. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(4);367-70{discussion :371-2}.
  8. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;3:1165-85.
  9. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999 Apr; 159(4 Pt 2):S1-40.
  10. Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. What we know and can do for our patients. Am J Respir Crit Care Med 2018 Jul 15;198(2):175-86.
  11. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010;36;81-8.
  12. Singer J, Yelin EH, Katz PP, Sanchez G, Iribarren C, Eisner MD, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev 2011 Mar-Apr;31(2):111-9.
  13. Cielen N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. BioMed Res Int 2014 Oct;2014.
  14. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010 Jul;36(1):81-8.
  15. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003 Sep;58(9):752-6.
  16. Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2:289-300.
  17. Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul) 2013;28:86-9.
  18. Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652-4.
  19. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019 Jan 1;48(1):16-31.
  20. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
  21. Majid H. Kanbar-Agha F, Sharafkhaneh A. COPD: osteoporosis and sarcopenia. COPD Res Prac 2016;2:3.
  22. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95.
  23. Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis 2016 Mar 29;11:637-48.
  24. Berry JL, Davies M, Mee AP. Vitamin D metabolism, rickets, and osteomalacia. Semin Musculoskelet Radiol 2002;6:173-82.
  25. Saghafi M, Azarian A, Hashemzadeh K, Sahebari M, Rezaieyazdi Z. Bone densitometry in patients with osteomalacia: is it valuable? Clin Cases Miner Bone Metab 2013 Sep;10(3):180-2.
  26. Abu-Bakr SM, Eldin MM, Hafez MR, Salem SM, Qandeel HT. Assessment of osteoporosis in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 2014 Jul 1;63(3):597-602.
  27. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011;22(6):1845-53.
  28. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011;22(6):1845-53.
  29. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009;341:209-18.
  30. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med 2012;12(1):1.
  31. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom 2018 Apr 6;3:e4.
  32. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, Chatzimavridou-Grigoriadou V, Siasos G, Evangelopoulou E, et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology 2013;18(1):147–153
  33. Langhammer A, Forsmo S, Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis 2009;4:365-80.
  34. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP; Endocrine Society, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30.
  35. Quint JK, Donaldson GC, Wassef N, Hurst JR, Thomas M, Wedzicha JA. 25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med 2012 Jun 22;12:28.
  36. Waterhouse JC, Perez TH, Albert PJ. Reversing Bacteria-induced Vitamin D Receptor Dysfunction Is Key to Autoimmune Disease. Ann New York Acad Sci 2009;1173(1):757–765.
  37. Ginde AA, Mansbach JM, Camargo CA Jr. Vitamin D, respiratory infections, and asthma. Curr Allergy Asthma Rep 2009 Jan;9(1):81-7.
  38. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012 Jan 17;156(2):105-14.
  39. Khan DM, Ullah A, Randhawa FA, Iqtadar S, Butt NF, Waheed K. Role of Vitamin D in reducing number of acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD) patients. Pak J Med Sci 2017;33(3):610-4.
  40. Kheradmand F, Shan M, Xu C, Corry DB. Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence. Expert Rev Clin Immunol 2012 Mar;8(3):285-92.
  41. Ma Y, Tong H, Zhang X, Wang M, Yang J, Wu M, et al. Chronic obstructive pulmonary disease in rheumatoid arthritis: a systematic review and meta-analysis. Respir Res 2019;20(1):144.
  42. Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, et al. Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results from the Nurses' Health Study. Arthritis Care Res (Hoboken) 2016 Jun; 68(6):753-62.
  43. Gergianaki I, Tsiligianni I. Chronic obstructive pulmonary disease and rheumatic diseases: A systematic review on a neglected comorbidity. J Comorb 2019;9:2235042X18820209.
  44. Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med1999;160 (5 Pt 2):S21-5.
  45. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
  46. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003 Oct;58(10):832-4.
  47. Packard TA, Li QZ, Cosgrove GP, Bowler RP, Cambier JC. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res 2013 Mar;55(1-3):48-57.
  48. Palmer MT, Weaver CT. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 2010;11:36-40.
  49. Shan M, Yuan X, Song L, Robert L, Zarinkamar N, Seryshev A, et al. Cigarette smoke induction of osteopontin (SPP1) mediates Th17 inflammation in human and experimental emphysema. Sci Transl Med 2012;4:117ra9.
  50. Birring SS, Brigtling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J, et al. Clinical, radiological and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 2002;166:1078-83.
  51. Núñez B, Sauleda J, Antó JM, Julià MR, Orozco M, Monsó E, et al. Anti-tissue antibodies are related to lung function impairment in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2011 Apr 15;183(8):1025-31.